Kazia Therapeutics announces the filing of provisional patent for novel strategy, supported by preclinical data, to prevent metastatic recurrence in triple-negative breast cancer ($12.21, 0.00)
StreetAccount Sector Summary - Healthcare Pre-Market
Roche receives FDA clearance for the cobas BV/CV assay, enabling fast and highly accurate vaginitis diagnosis (CHF 353.20, +3.70)
EMA CHMP publishes summary of opinions for July 2026 meeting
EU's CHMP adopted a positive opinion recommending the granting of a marketing authorisation for Susvimo (CHF 351.20, +1.70)
StreetAccount Sector Summary - Healthcare Post-Market
Transcript Intelligence: Roche Holding Q2 Earnings Guidance
Transcript Intelligence: Roche Holding Q2 Earnings Themes
Transcript Intelligence: Roche Holding Q2 Earnings Q&A
Powered by FactSet Research Systems Inc.